Through sessions and Community Hubs, attendees of ACR Convergence 2021 have multiple opportunities to connect with other rheumatology professionals. Here are some helpful tips from panelists.
Considerations for Prescribing Avacopan for ANCA-Associated Vasculitis
In early October, the FDA approved avacopan to treat anti-neutrophil cytoplasmic antibody associated vasculitis. Here are insights into the treatment’s risks and considerations.
The Clinical Value of Antiphospholipid Antibodies in Patients with COVID-19
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
ACR Convergence 2021: Advocacy Successes & Challenges
The ACR’s advocacy efforts over the past year have helped put critical prior authorization and step therapy legislation in front of Congress. Learn more at ACR Convergence 2021.
RheumPAC Hosts Rep. Mariannette Miller-Meeks, MD, in a Conversation on Healthcare Legislation
Earlier this month, RheumPAC donors joined the Iowa representative, an ophthalmologist, for a virtual discussion about healthcare legislation and how it can help specialty providers and their patients.
Business of Rheum Session to Outline What to Expect with MIPS Value Pathways
The MIPS Value Pathways will streamline federal reporting to better incentivize quality improvement. Start preparing for MVP with this session at ACR Convergence 2021.
Looking Forward to the Rheumatology MIPS Value Pathway
The field of rheumatology is leading the way in the Centers for Medicare and Medicaid Services’ new MIPS Value Pathways with rheumatology-specific quality measures and improvement activities.
Speak Up: Ask Congress to Block Medicare Reimbursement Cuts
Rheumatologists may need to downsize and restrict patient care if Congress doesn’t act to block significant cuts to Medicare reimbursement rates totaling 9.75% in 2022.
TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?
Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.
FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira
On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar…
- « Previous Page
- 1
- …
- 127
- 128
- 129
- 130
- 131
- …
- 816
- Next Page »